Group 1 - Eikon Therapeutics has officially submitted its IPO application to raise funds for its advanced drug pipeline, aiming for a listing in early 2026 [1] - The company plans to list on the NASDAQ under the ticker symbol "EIKN," with major underwriters including JPMorgan, Morgan Stanley, Bank of America, and Cantor Fitzgerald [1] - Eikon is led by former Merck executives Roger Perlmutter and Roy Baynes, who previously contributed to the development of pembrolizumab, the highest-grossing cancer therapy globally [1] Group 2 - Founded in 2019, Eikon has secured substantial funding, raising $350.7 million in a Series D round led by Lux Capital, Foresite Capital, Soros Fund Management, and accounts advised by T. Rowe Price [2] - As of September 30 last year, the company reported cash, cash equivalents, and short-term investments totaling $375.9 million [2] - The IPO application follows a trend of several companies, including Bob's Discount Furniture, Forgent Power Solutions, and Veradermics, also planning to go public in early 2026 [2]